ClinicalTrials.gg
CompletedNCT01397890SECURE 1Updated Mar 27, 2015Results posted

Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)

A Phase 4 interventional study of Budesonide/formoterol (Symbicort® Turbuhaler®) and Tiotropium (SpirivaTM) in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 30 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-03-27.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
793
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
47th of 194
793 · median 137
Started
2011
with 27 others
Phase 4
19 of 284
2 open now
Registered
101st of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 47th largest by enrollment of the 194 interventional ones that give a count, is one of 28 that started in 2011, is one of 19 in phase 4, and was the 101st registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

This is a multicentre study with a randomised, parallel group, open-label, 3-month phase IV design to assess the efficacy and tolerability of Symbicort as an add-on treatment to Spiriva compare with Spiriva alone in patients with severe chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Severe chronic obstructive pulmonary disease (COPD) patients
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated
  • Men or women patients ≥40 years of age
  • Diagnosis of with symptoms for more than 2 years and there is a history of at least one COPD exacerbation requiring a course of oral and/or antibiotics within 1-12 months before Visit 2
  • (FEV1) ≤50% of predicted normal value, pre-bronchodilator and Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) \< 70%, pre-bronchodilator
  • Total symptom score of 2 or more per day for at least half of run-in period (breathing, cough and sputum scores from the diary card) and complete morning recordings of Digital Peak Flow Meter data at least 7 out of the last 10 days of the run-in period

Exclusion criteria

Exclusion Criteria:

  • A history of asthma and seasonal allergic rhinitis before 40 years of age
  • Patients who have experienced exacerbation of requiring hospitalisation and /or emergency room treatment and/or a course of oral and/or intravenous corticosteroids and/or antibiotics within 4 weeks prior to Visit 2 and/or during run-in period and also the patients who use of systemic glucocorticosteroids (GCS) within 4 weeks and/or inhaled GCS within 2 weeks prior to Visit 2 and/or during run-in period
  • Patients with relevant cardiovascular disorder judged by the investigator
  • Patients with glaucoma, prostatic hyperplasia or bladder-neck obstruction judged by the investigator
  • Women who are pregnant, breast-feeding or of judged by the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
793 participants (actual)

Study arms

  • Other
    1

    Add-on treatment

    Drug: Budesonide/formoterol (Symbicort® Turbuhaler®) · Drug: Tiotropium (SpirivaTM)

  • Other
    2

    Add-on treatment

    Drug: Tiotropium (SpirivaTM)

Interventions

06

What researchers measure

Primary outcomes

  1. Pre-dose FEV1

    Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value

    Time frame: Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug

Secondary outcomes

  1. Post-dose FEV1 at 5 Minutes

    Ratio of post-dose FEV1 at 5 minutes to baseline value

    Time frame: Baseline (-2 weeks) and mean in treatment period (1, 6, 12 weeks) measured at 5 minutes after inhalation of study drug

  2. Post-dose FEV1 at 60 Minutes

    Ratio of post-dose FEV1 at 60 minutes to baseline value

    Time frame: Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)

  3. Pre-dose FVC

    Ratio of pre-dose FVC (Forced Vital Capacity) in treatment period to baseline value

    Time frame: Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)

  4. Post-dose FVC at 5 Minutes

    Ratio of post-dose FVC at 5 minutes to baseline value

    Time frame: Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 5 minutes after inhalation of study drug at weeks 0, 1, 6, 12)

  5. Post-dose FVC at 60 Minutes

    Ratio of post-dose FVC at 60 minutes to baseline value

    Time frame: Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)

  6. Pre-dose IC

    Ratio of pre-dose IC (Inspiratory Capacity) in treatment period to baseline value

    Time frame: Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug

  7. Post-dose IC at 60 Minutes

    Ratio of post-dose IC at 60 minutes to baseline value

    Time frame: Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)

  8. Pre-dose PEF in Last Week of Treatment

    Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the last week of treatment, up to 12 weeks

  9. Pre-dose PEF in First Week of Treatment

    Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to first week of treatment

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the first week of treatment

  10. Pre-dose PEF in Whole Treatment Period

    Change in pre-dose morning PEF from run-in period to whole treatment period

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in whole treatment period of 12 weeks

  11. Post-dose PEF in Last Week of Treatment

    Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the last week of treatment, up to 12 weeks

  12. Post-dose PEF in First Week of Treatment

    Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the first week of treatment

  13. Post-dose PEF in Whole Treatment Period

    Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in whole treatment period of 12 weeks

  14. Use of Reliever Medication During Day in the Last Week on Treatment

    Change in the number of inhalations of reliever medication during day from run-in period to the last week on treatment

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment, up to 12 weeks

  15. Use of Reliever Medication During Day in the First Week on Treatment

    Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the first week on treatment

  16. Use of Reliever Medication During Day in the Whole Treatment Period

    Change in the number of inhalations of reliever medication during day from run-in period to the whole treatment period

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period of 12 weeks

  17. Use of Reliever Medication During Night in the Last Week on Treatment

    Change in the number of inhalations of reliever medication during night from run-in period to the last week on treatment

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment, up to 12 weeks

  18. Use of Reliever Medication During Night in the First Week on Treatment

    Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the first week on treatment

  19. Use of Reliever Medication During Night in the Whole Treatment Period

    Change in the number of inhalations of reliever medication during night from run-in period to the whole treatment period

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period of 12 weeks

  20. Change in COPD Symptoms - Breathing

    Change in breathing symptom score (from 0:none to 4:severe) from run-in period

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks

  21. Change in COPD Symptoms - Cough

    Change in Cough symptom score (from 0:none to 4:severe) from run-in period

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks

  22. Change in COPD Symptoms - Sputum

    Change in Sputum symptom score (from 0:none to 4:severe) from run-in period

    Time frame: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks

  23. COPD Exacerbations

    Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms

    Time frame: Whole treatment period of 12 weeks

07

Results

Posted Aug 27, 2014

Participant flow

There are 793 patients enrolled. 578 patients were randomized, where there are 287 patients randomized in Symbicort+ Spiriva group and 291 in Spiriva group

Participant flow — Overall Study
MilestoneSymbicort+SpirivaSpiriva
Started287291
Post-baseline efficacy data collected287290
Received correct randomized treatment286287
Completed264260
Not completed2331
Withdrew: Withdrawal by subject711
Withdrew: Eligibility criteria not fulfilled76
Withdrew: Death23
Withdrew: Lost to follow-up14
Withdrew: Condition under investigation worsened13
Withdrew: Adverse event12
Withdrew: Severe non-compliance to protocol21
Withdrew: Others21

Outcome measures

PrimaryPre-dose FEV1

Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value

Time frame:
Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug
Reported as:
Geometric mean · Ratio
Pre-dose FEV1
RatioSymbicort+SpirivaSpiriva
Pre-dose FEV11.050 (1.030 to 1.070)1.006 (0.987 to 1.025)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.0004 · Ratio: 1.044 · 95% CI 1.019 to 1.069multiplicative ANCOVA model with treatment and country as fixed factors and baseline value as a (log-transformed) covariate
SecondaryPost-dose FEV1 at 5 Minutes

Ratio of post-dose FEV1 at 5 minutes to baseline value

Time frame:
Baseline (-2 weeks) and mean in treatment period (1, 6, 12 weeks) measured at 5 minutes after inhalation of study drug
Reported as:
Geometric mean · Ratio
Post-dose FEV1 at 5 Minutes
RatioSymbicort+SpirivaSpiriva
Post-dose FEV1 at 5 Minutes1.128 (1.109 to 1.147)1.045 (1.028 to 1.062)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Ratio: 1.079 · 95% CI 1.057 to 1.102Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.
SecondaryPost-dose FEV1 at 60 Minutes

Ratio of post-dose FEV1 at 60 minutes to baseline value

Time frame:
Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)
Reported as:
Geometric mean · Ratio
Post-dose FEV1 at 60 Minutes
RatioSymbicort+SpirivaSpiriva
Post-dose FEV1 at 60 Minutes1.164 (1.144 to 1.185)1.072 (1.053 to 1.091)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Ratio: 1.086 · 95% CI 1.062 to 1.111Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.
SecondaryPre-dose FVC

Ratio of pre-dose FVC (Forced Vital Capacity) in treatment period to baseline value

Time frame:
Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)
Reported as:
Geometric mean · Ratio
Pre-dose FVC
RatioSymbicort+SpirivaSpiriva
Pre-dose FVC1.032 (1.017 to 1.047)1.013 (0.999 to 1.029)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.0570 · Ratio: 1.018 · 95% CI 0.999 to 1.037Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.
SecondaryPost-dose FVC at 5 Minutes

Ratio of post-dose FVC at 5 minutes to baseline value

Time frame:
Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 5 minutes after inhalation of study drug at weeks 0, 1, 6, 12)
Reported as:
Geometric mean · Ratio
Post-dose FVC at 5 Minutes
RatioSymbicort+SpirivaSpiriva
Post-dose FVC at 5 Minutes1.096 (1.081 to 1.110)1.044 (1.030 to 1.057)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Ratio: 1.050 · 95% CI 1.033 to 1.067Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.
SecondaryPost-dose FVC at 60 Minutes

Ratio of post-dose FVC at 60 minutes to baseline value

Time frame:
Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)
Reported as:
Geometric mean · Ratio
Post-dose FVC at 60 Minutes
RatioSymbicort+SpirivaSpiriva
Post-dose FVC at 60 Minutes1.116 (1.100 to 1.132)1.059 (1.044 to 1.074)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Ratio: 1.054 · 95% CI 1.036 to 1.073Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.
SecondaryPre-dose IC

Ratio of pre-dose IC (Inspiratory Capacity) in treatment period to baseline value

Time frame:
Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug
Reported as:
Geometric mean · Ratio
Pre-dose IC
RatioSymbicort+SpirivaSpiriva
Pre-dose IC1.042 (1.017 to 1.068)1.022 (0.998 to 1.047)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.1956 · Ratio: 1.020 · 95% CI 0.990 to 1.050Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.
SecondaryPost-dose IC at 60 Minutes

Ratio of post-dose IC at 60 minutes to baseline value

Time frame:
Baseline (measured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)
Reported as:
Geometric mean · Ratio
Post-dose IC at 60 Minutes
RatioSymbicort+SpirivaSpiriva
Post-dose IC at 60 Minutes1.154 (1.129 to 1.180)1.087 (1.064 to 1.110)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Ratio: 1.062 · 95% CI 1.035 to 1.091Multiplicative ANCOVA model with treatment and country as fixed factors and week 0 pre-dose value as a (log-transformed) covariate.
SecondaryPre-dose PEF in Last Week of Treatment

Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the last week of treatment, up to 12 weeks
Reported as:
Least squares mean · L/min
Pre-dose PEF in Last Week of Treatment
L/minSymbicort+SpirivaSpiriva
Pre-dose PEF in Last Week of Treatment15.753 (7.306 to 24.200)-4.550 (-13.154 to 4.054)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.0001 · Mean difference (net): 20.303 · 95% CI 9.904 to 30.702Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryPre-dose PEF in First Week of Treatment

Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to first week of treatment

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the first week of treatment
Reported as:
Least squares mean · L/min
Pre-dose PEF in First Week of Treatment
L/minSymbicort+SpirivaSpiriva
Pre-dose PEF in First Week of Treatment13.405 (8.464 to 18.345)-0.182 (-4.994 to 4.630)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Mean difference (net): 13.587 · 95% CI 7.407 to 19.766Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryPre-dose PEF in Whole Treatment Period

Change in pre-dose morning PEF from run-in period to whole treatment period

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in whole treatment period of 12 weeks
Reported as:
Least squares mean · L/min
Pre-dose PEF in Whole Treatment Period
L/minSymbicort+SpirivaSpiriva
Pre-dose PEF in Whole Treatment Period12.271 (6.382 to 18.160)-5.198 (-10.925 to 0.530)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Mean difference (net): 17.469 · 95% CI 10.147 to 24.791Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryPost-dose PEF in Last Week of Treatment

Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the last week of treatment, up to 12 weeks
Reported as:
Least squares mean · L/min
Post-dose PEF in Last Week of Treatment
L/minSymbicort+SpirivaSpiriva
Post-dose PEF in Last Week of Treatment23.379 (13.199 to 33.560)-3.049 (-13.556 to 7.458)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.0001 · Mean difference (net): 26.428 · 95% CI 13.463 to 39.393Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryPost-dose PEF in First Week of Treatment

Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the first week of treatment
Reported as:
Least squares mean · L/min
Post-dose PEF in First Week of Treatment
L/minSymbicort+SpirivaSpiriva
Post-dose PEF in First Week of Treatment17.412 (9.349 to 25.476)0.220 (-7.486 to 7.926)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.0006 · Mean difference (net): 17.192 · 95% CI 7.491 to 26.894Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryPost-dose PEF in Whole Treatment Period

Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in whole treatment period of 12 weeks
Reported as:
Least squares mean · L/min
Post-dose PEF in Whole Treatment Period
L/minSymbicort+SpirivaSpiriva
Post-dose PEF in Whole Treatment Period15.880 (9.307 to 22.454)-2.591 (-9.063 to 3.880)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Mean difference (net): 18.472 · 95% CI 10.347 to 26.596Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryUse of Reliever Medication During Day in the Last Week on Treatment

Change in the number of inhalations of reliever medication during day from run-in period to the last week on treatment

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment, up to 12 weeks
Reported as:
Least squares mean · times/day
Use of Reliever Medication During Day in the Last Week on Treatment
times/daySymbicort+SpirivaSpiriva
Use of Reliever Medication During Day in the Last Week on Treatment-0.750 (-0.935 to 0.566)-0.082 (-0.267 to 0.103)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Mean difference (net): -0.668 · 95% CI -0.900 to -0.437Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryUse of Reliever Medication During Day in the First Week on Treatment

Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the first week on treatment
Reported as:
Least squares mean · times/day
Use of Reliever Medication During Day in the First Week on Treatment
times/daySymbicort+SpirivaSpiriva
Use of Reliever Medication During Day in the First Week on Treatment-0.457 (-0.598 to -0.316)-0.082 (-0.222 to 0.058)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Mean difference (net): -0.375 · 95% CI -0.552 to -0.198Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryUse of Reliever Medication During Day in the Whole Treatment Period

Change in the number of inhalations of reliever medication during day from run-in period to the whole treatment period

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period of 12 weeks
Reported as:
Least squares mean · times/day
Use of Reliever Medication During Day in the Whole Treatment Period
times/daySymbicort+SpirivaSpiriva
Use of Reliever Medication During Day in the Whole Treatment Period-0.685 (-0.836 to -0.533)-0.134 (-0.284 to 0.016)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Mean difference (net): -0.551 · 95% CI -0.741 to -0.361Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryUse of Reliever Medication During Night in the Last Week on Treatment

Change in the number of inhalations of reliever medication during night from run-in period to the last week on treatment

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment, up to 12 weeks
Reported as:
Least squares mean · times/day
Use of Reliever Medication During Night in the Last Week on Treatment
times/daySymbicort+SpirivaSpiriva
Use of Reliever Medication During Night in the Last Week on Treatment-0.174 (-0.299 to -0.049)0.062 (-0.062 to 0.187)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.0028 · Mean difference (net): -0.236 · 95% CI -0.391 to -0.082Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryUse of Reliever Medication During Night in the First Week on Treatment

Change in the number of inhalations of reliever medication during day from run-in period to the first week on treatment

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the first week on treatment
Reported as:
Least squares mean · times/day
Use of Reliever Medication During Night in the First Week on Treatment
times/daySymbicort+SpirivaSpiriva
Use of Reliever Medication During Night in the First Week on Treatment-0.113 (-0.206 to -0.019)0.011 (-0.081 to 0.104)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.0372 · Mean difference (net): -0.124 · 95% CI -0.240 to -0.007Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryUse of Reliever Medication During Night in the Whole Treatment Period

Change in the number of inhalations of reliever medication during night from run-in period to the whole treatment period

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period of 12 weeks
Reported as:
Least squares mean · times/day
Use of Reliever Medication During Night in the Whole Treatment Period
times/daySymbicort+SpirivaSpiriva
Use of Reliever Medication During Night in the Whole Treatment Period-0.241 (-0.336 to -0.147)-0.010 (-0.104 to 0.084)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.0001 · Mean difference (net): -0.231 · 95% CI -0.350 to -0.113Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryChange in COPD Symptoms - Breathing

Change in breathing symptom score (from 0:none to 4:severe) from run-in period

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks
Reported as:
Least squares mean · score on a scale
Change in COPD Symptoms - Breathing
score on a scaleSymbicort+SpirivaSpiriva
Change in COPD Symptoms - Breathing-0.372 (-0.454 to -0.290)-0.110 (-0.191 to -0.029)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = <0.0001 · Mean difference (net): -0.262 · 95% CI -0.364 to -0.159Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryChange in COPD Symptoms - Cough

Change in Cough symptom score (from 0:none to 4:severe) from run-in period

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks
Reported as:
Least squares mean · score on a scale
Change in COPD Symptoms - Cough
score on a scaleSymbicort+SpirivaSpiriva
Change in COPD Symptoms - Cough-0.311 (-0.394 to -0.229)-0.169 (-0.250 to -0.087)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.0067 · Mean difference (net): -0.143 · 95% CI -0.246 to -0.040Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryChange in COPD Symptoms - Sputum

Change in Sputum symptom score (from 0:none to 4:severe) from run-in period

Time frame:
Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period of 12 weeks
Reported as:
Least squares mean · score on a scale
Change in COPD Symptoms - Sputum
score on a scaleSymbicort+SpirivaSpiriva
Change in COPD Symptoms - Sputum-0.216 (-0.295 to -0.136)-0.094 (-0.173 to -0.014)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · ANCOVA · p = 0.0171 · Mean difference (net): -0.122 · 95% CI -0.222 to -0.022Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate
SecondaryCOPD Exacerbations

Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms

Time frame:
Whole treatment period of 12 weeks
Reported as:
Least squares mean · exacerbations/participant/12 weeks
COPD Exacerbations
exacerbations/participant/12 weeksSymbicort+SpirivaSpiriva
COPD Exacerbations0.182 (0.138 to 0.239)0.307 (0.248 to 0.379)
Statistical analysis
  • Symbicort+Spiriva vs Spiriva · Poisson regression · p = 0.0032 · Rate ratio: 0.593 · 95% CI 0.419 to 0.839Poisson regression model with treatment as a factor and the duration time in study as an offset variable morning PEF as a covariate
  • Symbicort+Spiriva vs Spiriva · Regression, Cox · p = 0.0167 · Cox proportional hazard: 0.614 · 95% CI 0.412 to 0.916Time to the first COPD exacerbation
  • Symbicort+Spiriva vs Spiriva · Log Rank · p = 0.0196

Adverse events

Collected over 12 weeks of treatment period. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symbicort+Spiriva—14/289 (4.8%)75/289 (26%)
Spiriva—24/289 (8.3%)76/289 (26.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventSymbicort+SpirivaSpiriva
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders7/28913/289
PneumoniaInfections and infestations2/2894/289
DyspnoeaRespiratory, thoracic and mediastinal disorders0/2891/289
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/2891/289
H1N1 influenzaInfections and infestations0/2891/289
Lower respiratory tract infectionInfections and infestations0/2891/289
InfluenzaInfections and infestations1/2890/289
HyperglycaemiaMetabolism and nutrition disorders0/2891/289
HypoglycaemiaMetabolism and nutrition disorders0/2891/289
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2891/289
Most frequent other events
Showing 10 of 73
Most frequent other events
EventSymbicort+SpirivaSpiriva
NasopharyngitisRespiratory, thoracic and mediastinal disorders6/28913/289
CoughRespiratory, thoracic and mediastinal disorders2/2897/289
MyalgiaMusculoskeletal and connective tissue disorders6/2891/289
BronchitisRespiratory, thoracic and mediastinal disorders5/2891/289
Sputum increasedRespiratory, thoracic and mediastinal disorders5/2891/289
DysphoniaRespiratory, thoracic and mediastinal disorders5/2890/289
Upper respiratory tract infectionInfections and infestations5/2893/289
Dry mouthGastrointestinal disorders3/2894/289
InfluenzaInfections and infestations4/2891/289
HeadacheNervous system disorders1/2894/289

Baseline characteristics

Overall Number of Baseline Participants is not different from the Milestones.

Age, Continuous
Age, Continuous(Years)Symbicort+SpirivaSpirivaTotal
Mean66.6 ± 7.9966.9 ± 8.5066.8 ± 8.25
Sex: Female, Male
Sex: Female, Male(Participants)Symbicort+SpirivaSpirivaTotal
Female81725
Male279273552
08

Study locations

30 sites
  • Research Site
    Beijing, Beijing, China
  • Research Site
    Guangzhou, Guangdong, China
  • Research Site
    Changsha, Hunan, China
  • Research Site
    Changchun, Jilin, China
  • Research Site
    Shen Yang, Liaoning, China
  • Research Site
    Shanghai, Shanghai, China
  • Research Site
    Taiyuan, Shanxi, China
  • Research Site
    Guang Zhou, China
  • Research Site
    Kowloon, HK, Hong Kong
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Jakarta, Indonesia
  • Research Site
    Solo, Indonesia
  • Research Site
    Surabaya, Indonesia
  • Research Site
    Wonju-si, Gangwon-do, Korea, Republic of
  • Research Site
    Suwon-si, Gyeonggi-do, Korea, Republic of
  • Research Site
    Jinju-si, Gyeongsangnam-do, Korea, Republic of
  • Research Site
    Busan, Korea, Republic of
  • Research Site
    Daegu, Korea, Republic of
  • Research Site
    Gwangju, Korea, Republic of
  • Research Site
    Incheon, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Muang, NAN, Thailand
  • Research Site
    Bangkok, Thailand
  • Research Site
    Chiang Mai, Thailand
  • Research Site
    Chonburi, Thailand
  • Research Site
    Khon Kaen, Thailand
  • Research Site
    Nonthaburi, Thailand
  • Research Site
    Phitsanulok, Thailand
  • Research Site
    Songkhla, Thailand
  • Research Site
    Udon Thani, Thailand
09

References and documents

Publications

  • Lee SD, Xie CM, Yunus F, Itoh Y, Ling X, Yu WC, Kiatboonsri S. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia. Respirology. 2016 Jan;21(1):119-27. doi: 10.1111/resp.12646. Epub 2015 Sep 23. PubMed 26394882 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2011
First posted
Jul 20, 2011
Start
Jul 2011
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Aug 27, 2014
Last update
Mar 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01397890
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 20, 2011
Start date
Jul 2011
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Aug 27, 2014
Last update
Mar 27, 2015

Study contacts

Samuel Chen, M.D.
study chair · AstraZeneca Pharmaceutical Co., Ltd., Shanghai, China
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol

Start the discussion